 One of the medicines that a great paper came out in AACR's journal, CCR, it was a medicine called Kavacantinib. And Kavacantinib is a wonderful medicine that dries up the blood supply, so blocks VEGF. It also blocks some of the growth mutations that are driving sarcomas. And so we found that when you combine a medication like Kavacantinib with immunotherapy, you can often get better results. And so a lot of this is in its very early stages of research. We do use the traditional chemotherapies in the advanced stage, but we're actually finding that in some cases we can get better results using targeted therapies and also immunotherapies.